Evotec AG has entered into a multi-year integrated drug discovery alliance with Genentech, a wholly owned member of the Roche Group, to advance the discovery of novel small molecule therapeutics.
Under the agreement, Evotec will apply its integrated and innovative drug discovery platform in combination with its extensive disease biology expertise against targets nominated by Genentech.
The aim of the collaboration will be to deliver development candidates to support Genentech’s research efforts and will include assay development and high throughput screening, medicinal chemistry and structural biology.
Commercial details were not released.
Share this article
